• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Overcoming Immunogenicity to Anti-TNF Therapy by Reactively Adding an Immunomodulator.

作者信息

Ward Mark G

机构信息

Alfred Hospital, Melbourne, Australia.

Central Clinical School, Monash University, Melbourne, Australia.

出版信息

Dig Dis Sci. 2024 Oct;69(10):3606-3607. doi: 10.1007/s10620-024-08620-5. Epub 2024 Sep 28.

DOI:10.1007/s10620-024-08620-5
PMID:39342065
Abstract
摘要

相似文献

1
Overcoming Immunogenicity to Anti-TNF Therapy by Reactively Adding an Immunomodulator.通过反应性添加免疫调节剂克服抗TNF治疗的免疫原性。
Dig Dis Sci. 2024 Oct;69(10):3606-3607. doi: 10.1007/s10620-024-08620-5. Epub 2024 Sep 28.
2
Anti-TNF Monotherapy for Crohn's Disease: a 13-year Multicentre Experience.抗 TNF 单药治疗克罗恩病：13 年多中心经验
J Crohns Colitis. 2016 May;10(5):516-24. doi: 10.1093/ecco-jcc/jjw008. Epub 2016 Jan 22.
3
Implications for sequencing of biologic therapy and choice of second anti-TNF in patients with inflammatory bowel disease: results from the IMmunogenicity to Second Anti-TNF therapy (IMSAT) therapeutic drug monitoring study.生物治疗药物的测序和炎症性肠病患者选择二线抗 TNF 治疗的意义：来自于第二代抗 TNF 治疗免疫原性（IMSAT）治疗药物监测研究的结果。
Aliment Pharmacol Ther. 2022 Oct;56(8):1250-1263. doi: 10.1111/apt.17170. Epub 2022 Aug 29.
4
Mechanisms and management of loss of response to anti-TNF therapy for patients with Crohn's disease: 3-year data from the prospective, multicentre PANTS cohort study.抗 TNF 治疗克罗恩病患者应答丧失的机制和管理：前瞻性、多中心 PANTS 队列研究的 3 年数据。
Lancet Gastroenterol Hepatol. 2024 Jun;9(6):521-538. doi: 10.1016/S2468-1253(24)00044-X. Epub 2024 Apr 16.
5
Suppression of anti-drug antibodies to infliximab or adalimumab with the addition of an immunomodulator in patients with inflammatory bowel disease.在炎症性肠病患者中添加免疫调节剂可抑制对英夫利昔单抗或阿达木单抗的抗药抗体。
Aliment Pharmacol Ther. 2017 Apr;45(8):1128-1134. doi: 10.1111/apt.13994. Epub 2017 Feb 23.
6
Effects of Concomitant Immunomodulator Therapy on Efficacy and Safety of Anti-Tumor Necrosis Factor Therapy for Crohn's Disease: A Meta-analysis of Placebo-controlled Trials.伴随免疫调节剂治疗对肿瘤坏死因子治疗克罗恩病疗效和安全性的影响：安慰剂对照试验的荟萃分析。
Clin Gastroenterol Hepatol. 2015 Dec;13(13):2233-40.e1-2; quiz e177-8. doi: 10.1016/j.cgh.2015.06.034. Epub 2015 Jun 30.
7
Anti-drug antibodies against anti-TNF in patients with inflammatory bowel disease: an evaluation of possible strategies.炎症性肠病患者针对抗 TNF 的抗药物抗体：可能策略的评估。
Scand J Gastroenterol. 2024 Jan-Jun;59(2):169-175. doi: 10.1080/00365521.2023.2278424. Epub 2024 Jan 30.
8
Prior Immunogenicity to Anti-TNF Biologics Is Not Associated with Increased Anti-drug Antibodies to Vedolizumab or Ustekinumab.先前对 TNF 拮抗剂的免疫原性与对维得利珠单抗或乌司奴单抗的抗药物抗体增加无关。
Dig Dis Sci. 2022 Jun;67(6):2480-2484. doi: 10.1007/s10620-021-07046-7. Epub 2021 May 21.
9
Immunomodulator comedication promotes the reversal of anti-drug antibody-mediated loss of response to anti-TNF therapy in inflammatory bowel disease.免疫调节剂联用可促进炎症性肠病患者对抗 TNF 治疗的药物抗体介导应答丧失的逆转。
Int J Colorectal Dis. 2023 Feb 25;38(1):54. doi: 10.1007/s00384-023-04349-1.
10
Long-Term Outcome of Infliximab Optimization for Overcoming Immunogenicity in Patients with Inflammatory Bowel Disease.英夫利昔单抗优化治疗克服炎症性肠病患者免疫原性的长期结局。
Dig Dis Sci. 2018 Mar;63(3):761-767. doi: 10.1007/s10620-018-4917-7. Epub 2018 Jan 16.

本文引用的文献

1
Reactive Immunomodulator Addition to Infliximab Monotherapy Restores Clinical Response in Inflammatory Bowel Disease: A Meta-Analysis.在英夫利昔单抗单药治疗中添加反应性免疫调节剂可恢复炎症性肠病的临床反应：一项荟萃分析。
Dig Dis Sci. 2024 Oct;69(10):3920-3931. doi: 10.1007/s10620-024-08515-5. Epub 2024 Jun 14.
2
HLA-DQ2 is associated with anti-drug antibody formation to infliximab in patients with immune-mediated inflammatory diseases.HLA-DQ2与免疫介导的炎症性疾病患者中抗英夫利昔单抗抗体的形成有关。
J Intern Med. 2023 May;293(5):648-655. doi: 10.1111/joim.13616. Epub 2023 Feb 26.
3
Dashboard-Driven Accelerated Infliximab Induction Dosing Increases Infliximab Durability and Reduces Immunogenicity.
仪表盘驱动的英夫利昔单抗加速诱导剂量可提高英夫利昔单抗的持久性并降低免疫原性。
Inflamm Bowel Dis. 2022 Sep 1;28(9):1375-1385. doi: 10.1093/ibd/izab285.
4
Addition of azathioprine to the switch of anti-TNF in patients with IBD in clinical relapse with undetectable anti-TNF trough levels and antidrug antibodies: a prospective randomised trial.在抗 TNF 治疗的 IBD 患者临床复发时，即使抗 TNF 药物浓度和抗药抗体检测不到，加用硫唑嘌呤转换方案：一项前瞻性随机试验。
Gut. 2020 Jul;69(7):1206-1212. doi: 10.1136/gutjnl-2019-319758. Epub 2020 Jan 24.
5
Immunogenicity of biologics in inflammatory bowel disease.生物制剂在炎症性肠病中的免疫原性。
Therap Adv Gastroenterol. 2018 Jan 21;11:1756283X17750355. doi: 10.1177/1756283X17750355. eCollection 2018.
6
Review article: acute severe ulcerative colitis - evidence-based consensus statements.综述文章：急性重度溃疡性结肠炎——循证共识声明。
Aliment Pharmacol Ther. 2016 Jul;44(2):127-44. doi: 10.1111/apt.13670. Epub 2016 May 26.
7
The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab.英夫利昔单抗治疗炎症性肠病患者的抗药物抗体的时间演变。
Gut. 2014 Aug;63(8):1258-64. doi: 10.1136/gutjnl-2013-305259. Epub 2013 Sep 16.